Alexion Pharmaceuticals has partnered with Complement Pharma for the co-development of pre-clinical complement inhibitor for neurodegenerative disorders.
The two companies will collaborate on the development programme for CP010, a humanised monoclonal antibody that prevents MAC formation in both the periphery and the central nervous system.
Based in the US, Alexion is a pharmaceutical company focused on the development of medicines for rare diseases, while Complement Pharma is a Netherlands-based developer of proprietary monoclonal antibodies.
Recipharm has completed the acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel, UK, for £45m ($60.11m).
Based in Sweden, Recipharm is a pharmaceutical development and manufacturing company, while Sanofi is a US-based pharmaceutical company that develops vaccines.
The acquisition will enable Recipharm to gain access to new customers and increase its business in the respiratory drug market.
Genentech has teamed up with Microbiotica to develop microbiome-based inflammatory bowel disease (IBD) medicines.
The two companies will focus on the discovery, development and commercialisation of microbiome-based biomarkers and therapies for IBD.
Genentech will pay an undisclosed upfront payment to Microbiotica and an additional $534m in milestone payments, as part of the agreement.
Based in the US, Genentech is a biotechnology company that develops innovative medicines, while Microbiotica is a UK-based developer of therapies based on microbiome science.
The partnership will enable Microbiotica to expand its reference genome database and culture collection.
Sanofi Pasteur has partnered with Translate Bio to develop new vaccines for infectious diseases using mRNA technology.
Sanofi will make an upfront payment of $45m to Translate Bio, as well as $805m in milestone payments, as part of the agreement.
Sanofi will sponsor the research costs and retain the commercialisation rights of the vaccines developed, while Translate will be responsible for the clinical development of the vaccines.
Based in the US, Sanofi is a pharmaceutical company, while Translate Bio, also based in the US, is a provider of medicines that help to treat gene dysfunctions.
Aurora Cannabis has signed an agreement to acquire Anandia Laboratories (Anandia) for $115m.
Aurora will buy all the issued and outstanding shares from Anandia’s shareholders in an all-share transaction valued at approximately $115m.
Based in Canada, Aurora Cannabis is a producer and distributor of cannabis products, while Anandia, also based in Canada, is a cannabis biotechnology company.
The deal will be closed subject to customary closing conditions and regulatory approvals.
LabCorp has completed the acquisition of Sciformix Corporation for an undisclosed sum.
Sciformix will operate as part of Covance, LabCorp’s drug development business.
Based in the US, LabCorp is a life sciences company specialising in healthcare, while Sciformix, also based in the US, is a provider of biopharmaceutical and medical devices.
The transaction will enable the acquirer company to strengthen its position in the drug and device development market.